NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
March 27, 2007 • Volume 4 / Number 13 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Second Cancers Deserve More Attention

Director's Update
Strong Leadership for Scientific Progress

Cancer Research Highlights
Imatinib 'Treatment Holiday' Risks Disease Progression

Annual Zoledronic Acid Increases Bone Density in Prostate Cancer Patients

Surgery Does Not Improve Survival for Advanced NSCLC Patients

Hodgkin Lymphoma Survivors Have Increased Lifetime Risk of Solid Cancers

Special Report
Standards for Basic Research May Speed Clinical Tests

Featured Clinical Trial
Cilengitide for PSA-Only Progressive Prostate Cancer

Notes
Azad Receives Young Investigator's Award

CDC Promotes Eating More Fruits and Vegetables

DCLG to Meet This Week

NCI Cosponsors Conference in India

Funding Opportunites

NCI 70th Anniversary: If Memory Serves...

Community Update
New NIH Roadmap Initiatives Proposals Announced

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

Second Cancers Deserve More Attention

More than 10 million people in the United States are living with cancer, a population of survivors that has tripled in size since 1970. Long-term survivors face increased risk of many health problems, including subsequent cancer, either by recurrence of their original disease or a new primary cancer.

A new analysis from scientists at the Division of Cancer Control and Population Sciences (DCCPS) used Surveillance, Epidemiology and End Results (SEER) data to develop what they believe is the first population-based estimate of the number of people living who have had a diagnosis of more than one primary cancer.  Read more  



Director's Update

Strong Leadership for Scientific Progress

Dr. Lee Helman (center) in his lab at NCI's Center for Cancer ResearchI am very pleased to announce that Drs. Robert H. Wiltrout and Lee Helman have been appointed as Scientific Directors (SD) of NCI's Center for Cancer Research (CCR). Both have been serving in acting roles: Dr. Wiltrout as the SD for CCR and Dr. Helman serving under him as the SD for Clinical Research. Drs. Wiltrout and Helman have filled these positions superbly on an acting basis for the last several years.

Dr. Wiltrout's leadership of CCR has been unparalleled. He has done an excellent job of leading CCR in the current budgetary environment and has championed the importance of innovative, collaborative research, including overseeing the creation of four CCR Centers of Excellence to foster team science.  Read more  


The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov